Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Integra LifeSciences Holdings Corporation. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Integra LifeSciences Holdings Corporation (IART) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation (“Integra LifeSciences” or “the Company”) (NASDAQ: IART). Investors who purchased Integra LifeSciences securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Integra LifeSciences has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On October 2, 2026, Integra LifeSciences Holdings Corporation lowered its full-year 2026 guidance and reported preliminary third-quarter revenue below analyst estimates. The Company attributed the guidance reduction and revenue shortfall to a July flood at its Cincinnati manufacturing facility, which damaged production assets and disrupted product supply. Integra stated that the disruption is expected to reduce fourth-quarter revenue by approximately $15 million to $20 million, with full manufacturing operations at the facility not expected to resume until the second quarter of 2027. During the Company’s July 29, 2026, earnings call, Chief Financial Officer Lea Daniels Knight had stated that Integra did “not expect the event to have a material impact on our revenue or EPS guidance for 2026.” Following this news, Integra’s stock price fell nearly 20% in midday trading on October 2, 2026.
What Should Integra LifeSciences Holdings Corporation (IART) Investors Do?
If you are aware of any facts relating to this investigation or purchased Integra LifeSciences securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Is Integra LifeSciences Holdings Corporation (NASDAQ: IART) Stock Trading Today?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”